AlzeCure Pharma AB (FRA:AC6) Moat Score: 0/10 (As of Jul. 13, 2026)


FRA:AC6 AlzeCure Pharma AB FRA:AC6
33 GF Score
Price €0.53
! 1 Warning Sign
View Full Analysis

What is AlzeCure Pharma AB Moat Score?

AlzeCure Pharma AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

AlzeCure Pharma AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes AlzeCure Pharma AB might have No Moat - No discernible moat.

AlzeCure Pharma AB  (FRA:AC6) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

AlzeCure Pharma AB Moat Score Related Terms

FRA:AC6
33GF Score
AlzeCure Pharma AB FRA:AC6
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AlzeCure Pharma AB Business Description

Other Exchanges ALZCUR:Sweden
Address Halsovagen 7, Huddinge, SWE, SE 141 57
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in drug research with a primary focus on Alzheimer's disease. The company develops several drugs within its three research platforms, NeuroRestore, Alzstatin, and Painless. The company's drug candidates include: ACD440, which is in the clinical development phase for the treatment of neuropathic pain, ACD856, ACD857, and ACD680 for the treatment of Alzheimer's disease, and ACD137 for the treatment of severe pain in conditions such as osteoarthritis.
33GF Score

Get the complete analysis for FRA:AC6

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.53
Price